Does CT-based Rigidity Analysis Influence Clinical Decision-making in Simulations of Metastatic Bone Disease?

Ara Nazarian, Vahid Entezari, Juan C. Villa-Camacho, David Zurakowski, Jeffrey N. Katz, Mary Hochman, Elizabeth H. Baldini, Vartan Vartanians, Max P. Rosen, Mark C. Gebhardt, Richard M. Terek, Timothy A. Damron, Michael J Yaszemski, Brian D. Snyder

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: There is a need to improve the prediction of fracture risk for patients with metastatic bone disease. CT-based rigidity analysis (CTRA) is a sensitive and specific method, yet its influence on clinical decision-making has never been quantified. Questions/purposes: What is the influence of CTRA on providers’ perceived risk of fracture? (2) What is the influence of CTRA on providers’ treatment recommendations in simulated clinical scenarios of metastatic bone disease of the femur? (3) Does CTRA improve interobserver agreement regarding treatment recommendations? Methods: We conducted a survey among 80 academic physicians (orthopaedic oncologists, musculoskeletal radiologists, and radiation oncologists) using simulated vignettes of femoral lesions presented as three separate scenarios: (1) no CTRA input (baseline); (2) CTRA input suggesting increased risk of fracture (CTRA+); and (3) CTRA input suggesting decreased risk of fracture (CTRA−). Participants were asked to rate the patient’s risk of fracture on a scale of 0% to 100% and to provide a treatment recommendation. Overall response rate was 62.5% (50 of 80). Results: When CTRA suggested an increased risk of fracture, physicians perceived the fracture risk to be slightly greater (37% ± 3% versus 42% ± 3%, p <0.001; mean difference [95% confidence interval {CI}] = 5% [4.7%–5.2%]) and were more prone to recommend surgical stabilization (46% ± 9% versus 54% ± 9%, p <0.001; mean difference [95% CI] = 9% [7.9–10.1]). When CTRA suggested a decreased risk of fracture, physicians perceived the risk to be slightly decreased (37% ± 25% versus 35% ± 25%, p = 0.04; mean difference [95% CI] = 2% [2.74%–2.26%]) and were less prone to recommend surgical stabilization (46% ± 9% versus 42% ± 9%, p <0.03; mean difference [95% CI] = 4% [3.9–5.1]). The effect size of the influence of CTRA on physicians’ perception of fracture risk and treatment planning varied with lesion severity and specialty of the responders. CTRA did not increase interobserver agreement regarding treatment recommendations when compared with the baseline scenario (κ = 0.41 versus κ = 0.43, respectively). Conclusions: Based on this survey study, CTRA had a small influence on perceived fracture risk and treatment recommendations and did not increase interobserver agreement. Further work is required to properly introduce this technique to physicians involved in the care of patients with metastatic lesions. Given the number of preclinical and clinical studies outlining the efficacy of this technique, better education through presentations at seminars/webinars and symposia will be the first step. This should be followed by clinical trials to establish CTRA-based clinical guidelines based on evidence-based medicine. Increased exposure of clinicians to CTRA, including its underlying methodology to study bone structural characteristics, may establish CTRA as a uniform guideline to assess fracture risk. Level of Evidence: Level III, economic and decision analyses.

Original languageEnglish (US)
Pages (from-to)652-659
Number of pages8
JournalClinical Orthopaedics and Related Research
Volume474
Issue number3
DOIs
StatePublished - Mar 1 2016

Fingerprint

Bone Diseases
Physicians
Confidence Intervals
Clinical Decision-Making
Therapeutics
Guidelines
Decision Support Techniques
Evidence-Based Medicine
Thigh
Femur
Orthopedics
Patient Care
Economics
Clinical Trials

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine

Cite this

Nazarian, A., Entezari, V., Villa-Camacho, J. C., Zurakowski, D., Katz, J. N., Hochman, M., ... Snyder, B. D. (2016). Does CT-based Rigidity Analysis Influence Clinical Decision-making in Simulations of Metastatic Bone Disease? Clinical Orthopaedics and Related Research, 474(3), 652-659. https://doi.org/10.1007/s11999-015-4371-1

Does CT-based Rigidity Analysis Influence Clinical Decision-making in Simulations of Metastatic Bone Disease? / Nazarian, Ara; Entezari, Vahid; Villa-Camacho, Juan C.; Zurakowski, David; Katz, Jeffrey N.; Hochman, Mary; Baldini, Elizabeth H.; Vartanians, Vartan; Rosen, Max P.; Gebhardt, Mark C.; Terek, Richard M.; Damron, Timothy A.; Yaszemski, Michael J; Snyder, Brian D.

In: Clinical Orthopaedics and Related Research, Vol. 474, No. 3, 01.03.2016, p. 652-659.

Research output: Contribution to journalArticle

Nazarian, A, Entezari, V, Villa-Camacho, JC, Zurakowski, D, Katz, JN, Hochman, M, Baldini, EH, Vartanians, V, Rosen, MP, Gebhardt, MC, Terek, RM, Damron, TA, Yaszemski, MJ & Snyder, BD 2016, 'Does CT-based Rigidity Analysis Influence Clinical Decision-making in Simulations of Metastatic Bone Disease?', Clinical Orthopaedics and Related Research, vol. 474, no. 3, pp. 652-659. https://doi.org/10.1007/s11999-015-4371-1
Nazarian, Ara ; Entezari, Vahid ; Villa-Camacho, Juan C. ; Zurakowski, David ; Katz, Jeffrey N. ; Hochman, Mary ; Baldini, Elizabeth H. ; Vartanians, Vartan ; Rosen, Max P. ; Gebhardt, Mark C. ; Terek, Richard M. ; Damron, Timothy A. ; Yaszemski, Michael J ; Snyder, Brian D. / Does CT-based Rigidity Analysis Influence Clinical Decision-making in Simulations of Metastatic Bone Disease?. In: Clinical Orthopaedics and Related Research. 2016 ; Vol. 474, No. 3. pp. 652-659.
@article{0c7291ae42ca4586b1b81e2cd4c75f6c,
title = "Does CT-based Rigidity Analysis Influence Clinical Decision-making in Simulations of Metastatic Bone Disease?",
abstract = "Background: There is a need to improve the prediction of fracture risk for patients with metastatic bone disease. CT-based rigidity analysis (CTRA) is a sensitive and specific method, yet its influence on clinical decision-making has never been quantified. Questions/purposes: What is the influence of CTRA on providers’ perceived risk of fracture? (2) What is the influence of CTRA on providers’ treatment recommendations in simulated clinical scenarios of metastatic bone disease of the femur? (3) Does CTRA improve interobserver agreement regarding treatment recommendations? Methods: We conducted a survey among 80 academic physicians (orthopaedic oncologists, musculoskeletal radiologists, and radiation oncologists) using simulated vignettes of femoral lesions presented as three separate scenarios: (1) no CTRA input (baseline); (2) CTRA input suggesting increased risk of fracture (CTRA+); and (3) CTRA input suggesting decreased risk of fracture (CTRA−). Participants were asked to rate the patient’s risk of fracture on a scale of 0{\%} to 100{\%} and to provide a treatment recommendation. Overall response rate was 62.5{\%} (50 of 80). Results: When CTRA suggested an increased risk of fracture, physicians perceived the fracture risk to be slightly greater (37{\%} ± 3{\%} versus 42{\%} ± 3{\%}, p <0.001; mean difference [95{\%} confidence interval {CI}] = 5{\%} [4.7{\%}–5.2{\%}]) and were more prone to recommend surgical stabilization (46{\%} ± 9{\%} versus 54{\%} ± 9{\%}, p <0.001; mean difference [95{\%} CI] = 9{\%} [7.9–10.1]). When CTRA suggested a decreased risk of fracture, physicians perceived the risk to be slightly decreased (37{\%} ± 25{\%} versus 35{\%} ± 25{\%}, p = 0.04; mean difference [95{\%} CI] = 2{\%} [2.74{\%}–2.26{\%}]) and were less prone to recommend surgical stabilization (46{\%} ± 9{\%} versus 42{\%} ± 9{\%}, p <0.03; mean difference [95{\%} CI] = 4{\%} [3.9–5.1]). The effect size of the influence of CTRA on physicians’ perception of fracture risk and treatment planning varied with lesion severity and specialty of the responders. CTRA did not increase interobserver agreement regarding treatment recommendations when compared with the baseline scenario (κ = 0.41 versus κ = 0.43, respectively). Conclusions: Based on this survey study, CTRA had a small influence on perceived fracture risk and treatment recommendations and did not increase interobserver agreement. Further work is required to properly introduce this technique to physicians involved in the care of patients with metastatic lesions. Given the number of preclinical and clinical studies outlining the efficacy of this technique, better education through presentations at seminars/webinars and symposia will be the first step. This should be followed by clinical trials to establish CTRA-based clinical guidelines based on evidence-based medicine. Increased exposure of clinicians to CTRA, including its underlying methodology to study bone structural characteristics, may establish CTRA as a uniform guideline to assess fracture risk. Level of Evidence: Level III, economic and decision analyses.",
author = "Ara Nazarian and Vahid Entezari and Villa-Camacho, {Juan C.} and David Zurakowski and Katz, {Jeffrey N.} and Mary Hochman and Baldini, {Elizabeth H.} and Vartan Vartanians and Rosen, {Max P.} and Gebhardt, {Mark C.} and Terek, {Richard M.} and Damron, {Timothy A.} and Yaszemski, {Michael J} and Snyder, {Brian D.}",
year = "2016",
month = "3",
day = "1",
doi = "10.1007/s11999-015-4371-1",
language = "English (US)",
volume = "474",
pages = "652--659",
journal = "Clinical Orthopaedics and Related Research",
issn = "0009-921X",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Does CT-based Rigidity Analysis Influence Clinical Decision-making in Simulations of Metastatic Bone Disease?

AU - Nazarian, Ara

AU - Entezari, Vahid

AU - Villa-Camacho, Juan C.

AU - Zurakowski, David

AU - Katz, Jeffrey N.

AU - Hochman, Mary

AU - Baldini, Elizabeth H.

AU - Vartanians, Vartan

AU - Rosen, Max P.

AU - Gebhardt, Mark C.

AU - Terek, Richard M.

AU - Damron, Timothy A.

AU - Yaszemski, Michael J

AU - Snyder, Brian D.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Background: There is a need to improve the prediction of fracture risk for patients with metastatic bone disease. CT-based rigidity analysis (CTRA) is a sensitive and specific method, yet its influence on clinical decision-making has never been quantified. Questions/purposes: What is the influence of CTRA on providers’ perceived risk of fracture? (2) What is the influence of CTRA on providers’ treatment recommendations in simulated clinical scenarios of metastatic bone disease of the femur? (3) Does CTRA improve interobserver agreement regarding treatment recommendations? Methods: We conducted a survey among 80 academic physicians (orthopaedic oncologists, musculoskeletal radiologists, and radiation oncologists) using simulated vignettes of femoral lesions presented as three separate scenarios: (1) no CTRA input (baseline); (2) CTRA input suggesting increased risk of fracture (CTRA+); and (3) CTRA input suggesting decreased risk of fracture (CTRA−). Participants were asked to rate the patient’s risk of fracture on a scale of 0% to 100% and to provide a treatment recommendation. Overall response rate was 62.5% (50 of 80). Results: When CTRA suggested an increased risk of fracture, physicians perceived the fracture risk to be slightly greater (37% ± 3% versus 42% ± 3%, p <0.001; mean difference [95% confidence interval {CI}] = 5% [4.7%–5.2%]) and were more prone to recommend surgical stabilization (46% ± 9% versus 54% ± 9%, p <0.001; mean difference [95% CI] = 9% [7.9–10.1]). When CTRA suggested a decreased risk of fracture, physicians perceived the risk to be slightly decreased (37% ± 25% versus 35% ± 25%, p = 0.04; mean difference [95% CI] = 2% [2.74%–2.26%]) and were less prone to recommend surgical stabilization (46% ± 9% versus 42% ± 9%, p <0.03; mean difference [95% CI] = 4% [3.9–5.1]). The effect size of the influence of CTRA on physicians’ perception of fracture risk and treatment planning varied with lesion severity and specialty of the responders. CTRA did not increase interobserver agreement regarding treatment recommendations when compared with the baseline scenario (κ = 0.41 versus κ = 0.43, respectively). Conclusions: Based on this survey study, CTRA had a small influence on perceived fracture risk and treatment recommendations and did not increase interobserver agreement. Further work is required to properly introduce this technique to physicians involved in the care of patients with metastatic lesions. Given the number of preclinical and clinical studies outlining the efficacy of this technique, better education through presentations at seminars/webinars and symposia will be the first step. This should be followed by clinical trials to establish CTRA-based clinical guidelines based on evidence-based medicine. Increased exposure of clinicians to CTRA, including its underlying methodology to study bone structural characteristics, may establish CTRA as a uniform guideline to assess fracture risk. Level of Evidence: Level III, economic and decision analyses.

AB - Background: There is a need to improve the prediction of fracture risk for patients with metastatic bone disease. CT-based rigidity analysis (CTRA) is a sensitive and specific method, yet its influence on clinical decision-making has never been quantified. Questions/purposes: What is the influence of CTRA on providers’ perceived risk of fracture? (2) What is the influence of CTRA on providers’ treatment recommendations in simulated clinical scenarios of metastatic bone disease of the femur? (3) Does CTRA improve interobserver agreement regarding treatment recommendations? Methods: We conducted a survey among 80 academic physicians (orthopaedic oncologists, musculoskeletal radiologists, and radiation oncologists) using simulated vignettes of femoral lesions presented as three separate scenarios: (1) no CTRA input (baseline); (2) CTRA input suggesting increased risk of fracture (CTRA+); and (3) CTRA input suggesting decreased risk of fracture (CTRA−). Participants were asked to rate the patient’s risk of fracture on a scale of 0% to 100% and to provide a treatment recommendation. Overall response rate was 62.5% (50 of 80). Results: When CTRA suggested an increased risk of fracture, physicians perceived the fracture risk to be slightly greater (37% ± 3% versus 42% ± 3%, p <0.001; mean difference [95% confidence interval {CI}] = 5% [4.7%–5.2%]) and were more prone to recommend surgical stabilization (46% ± 9% versus 54% ± 9%, p <0.001; mean difference [95% CI] = 9% [7.9–10.1]). When CTRA suggested a decreased risk of fracture, physicians perceived the risk to be slightly decreased (37% ± 25% versus 35% ± 25%, p = 0.04; mean difference [95% CI] = 2% [2.74%–2.26%]) and were less prone to recommend surgical stabilization (46% ± 9% versus 42% ± 9%, p <0.03; mean difference [95% CI] = 4% [3.9–5.1]). The effect size of the influence of CTRA on physicians’ perception of fracture risk and treatment planning varied with lesion severity and specialty of the responders. CTRA did not increase interobserver agreement regarding treatment recommendations when compared with the baseline scenario (κ = 0.41 versus κ = 0.43, respectively). Conclusions: Based on this survey study, CTRA had a small influence on perceived fracture risk and treatment recommendations and did not increase interobserver agreement. Further work is required to properly introduce this technique to physicians involved in the care of patients with metastatic lesions. Given the number of preclinical and clinical studies outlining the efficacy of this technique, better education through presentations at seminars/webinars and symposia will be the first step. This should be followed by clinical trials to establish CTRA-based clinical guidelines based on evidence-based medicine. Increased exposure of clinicians to CTRA, including its underlying methodology to study bone structural characteristics, may establish CTRA as a uniform guideline to assess fracture risk. Level of Evidence: Level III, economic and decision analyses.

UR - http://www.scopus.com/inward/record.url?scp=84957849117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957849117&partnerID=8YFLogxK

U2 - 10.1007/s11999-015-4371-1

DO - 10.1007/s11999-015-4371-1

M3 - Article

VL - 474

SP - 652

EP - 659

JO - Clinical Orthopaedics and Related Research

JF - Clinical Orthopaedics and Related Research

SN - 0009-921X

IS - 3

ER -